RCKT - Rocket Pharma initiated Buy at Needham citing AAV-based gene therapy

The decision by bluebird bio ([[BLUE]] -3.4%) to suspend two clinical trials involving its lentiviral vector-based gene therapy candidate, LentiGlobin hurt other biotech developers such as Rocket Pharmaceuticals ([[RCKT]] +0.0%) whose portfolio have lentiviral vector-based experimental therapies.However, Rocket Pharma is a standout among them today as Needham initiates the coverage on the stock with a buy and a price target of ~$75.00, implying ~42.5% upside to the previous close.The analyst Gil Blum expects two of the company’s lentiviral candidates RP-L102 and RP-L201 to reach the market first while highlighting RP-A501, AAV9-based gene therapy for Danon disease as a ‘major value driver.’All three programs and another lentiviral vector-based gene therapy, RP-L301 in pyruvate kinase deficiency have upcoming data readouts in 2021, the analyst observes.Seeking Alpha contributor Biologics commented in a recent neutral thesis on Rocket Pharma: ‘Although I am still bullish on the company prospects, I am not looking to buy at these prices at

For further details see:

Rocket Pharma initiated Buy at Needham citing AAV-based gene therapy